2,016
Participants
Start Date
March 10, 2024
Primary Completion Date
March 31, 2027
Study Completion Date
April 30, 2027
Treatment of severe malaria with rectal artesunate + Artemisinin based Combination Therapy is not inferior to rectal artesunate + injectable artesunate + ACT in terms of effectiveness in remote areas
The Community Health Worker will give rectal artesunate (RAS) +artemisinin based combination Therapy (ACT) to children aged 6 months to less than or equal to 5 years who fail to make the referral trip. Those who make the referral trip will receive injectable artesunate and artemisinin based Combination Therapy for three days. Giving of RAS +ACT is unique to this study. Children with non malaria severe disease will also receive amoxicillin from the community health worker before they are referred to the next level of care
Tropical Diseases Research Centre, Ndola
University of Kinshasa, Kinshasa
Universiteit Antwerpen
OTHER
University of Kinshasa
OTHER
National Institute for Medical Research, Tanzania
OTHER_GOV
Medicines for Malaria Venture
OTHER
Université de Lubumbashi
OTHER
Tropical Diseases Research Centre, Zambia
OTHER_GOV